Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2019-11-26
2021-07-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3361237 in Participants With Psoriasis
NCT04975295
A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
NCT03418493
A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis
NCT04152382
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06176768
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Participants received placebo administered subcutaneously (SC) every 2 weeks for a period of 12 weeks.
Placebo
Administered SC
Cohort 1 - 10 (Microgram Per Kilogram) μg/kg LY3471851
Participants received 10 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
LY3471851
Administered SC
Cohort 2 - 24 μg/kg LY3471851
Participants received 24 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
LY3471851
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Administered SC
LY3471851
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have active psoriasis plaques according to study- specific criteria
* Be willing and able to undergo skin biopsies
Exclusion Criteria
* Have received certain systemic medications for psoriasis within 4 weeks prior to baseline
* Have received LY3471851 previously
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Nektar Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Nektar Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States
California Dermatology & Clinical Research Institute
Encinitas, California, United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States
Therapeutics Clinical Research
San Diego, California, United States
Clinical Science Institute
Santa Monica, California, United States
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida, United States
Miami Dermatology and Laser Research
Miami, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
Medical Dermatology Specialists
Sandy Springs, Georgia, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Skin Sciences
Louisville, Kentucky, United States
Forefront Research
Louisville, Kentucky, United States
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, United States
Derm Center
Troy, Michigan, United States
Central Dermatology PC
St Louis, Missouri, United States
ActivMed Practices and Research
Portsmouth, New Hampshire, United States
Remington-Davis, Inc
Columbus, Ohio, United States
Unity Clinical Research
Oklahoma City, Oklahoma, United States
Paddington Testing Company Inc
Philadelphia, Pennsylvania, United States
DermDox Centers for Dermatology
Sugarloaf, Pennsylvania, United States
Studies in Dermatology, LLC
Cypress, Texas, United States
Rodgers Dermatology
Frisco, Texas, United States
Progressive Clinical Research
San Antonio, Texas, United States
Complete Dermatology
Sugar Land, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, Schleicher S, Beck L, Gooderham M, Chaudhry S, Fanton C, Yu D, Levy J, Liu Y, Miyazaki T, Tagliaferri M, Schmitz C, Nirula A, Kotzin B, Zalevsky J. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat Commun. 2024 Oct 25;15(1):9230. doi: 10.1038/s41467-024-53384-1.
Related Links
Access external resources that provide additional context or updates about the study.
A Study of LY3471851 in Participants With Psoriasis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J1P-MC-KFAC
Identifier Type: OTHER
Identifier Source: secondary_id
17239
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.